SRRK News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

SR

Mkt Cap

$4.86B

Volume

2.44M

Next Earnings

November 13th

Loading chart

SR

SRRKScholar Rock Holding Corporation Common Stock

SRRK

Pay with—

Available Balance0.00

SR

Mkt Cap

$4.95B

Volume

2.44M

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

FDA Approves Isembyld (apitegromab-mstn), the First and Only Muscle-Targeted Therapy for Spinal Muscular Atrophy, Marking a New Milestone in SMA TreatmentThe FDA has approved Isembyld (apitegromab-mstn), the first muscle-targeted therapy for spinal muscular atrophy (SMA) that works alongside existing SMN-targeted treatments. The approval is based on positive Phase 3 SAPPHIRE study results showing clinically meaningful improvements in motor function. This milestone represents a shift from slowing SMA progression to improving patient function and quality of life.GlobeNewswire Inc. · Sep 11, 2026

Scholar Rock Chief Scientific Officer Conducts Multiple Sales Throughout January 2026Scholar Rock's Chief Scientific Officer Mo Qatanani sold 14,898 shares on January 22, 2026, for approximately $695,938 as part of a pre-planned Rule 10b5-1 trading plan. The sale reduced his direct ownership to 85,660 shares (0.08% of outstanding shares). The company plans to launch its key product candidate apitegromab in U.S. and European markets in 2026, positioning it as a potential treatment for spinal muscular atrophy.The Motley Fool · Feb 1, 2026

Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked AwayCommodore Capital fully exited its position in Scholar Rock, selling approximately 1.5 million shares in Q3, representing a $51 million transaction. The biotech company is preparing to resubmit its apitegromab biologics license application after a previous FDA rejection.The Motley Fool · Dec 3, 2025

FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And AdultsThe FDA approved Novartis' Itvisma, a gene replacement therapy for spinal muscular atrophy (SMA), which can treat patients two years and older by addressing the genetic root cause of the disease with a one-time fixed dose.Benzinga · Nov 25, 2025

Why Scholar Rock Stock Got Socked on MondayScholar Rock's stock dropped over 13% after the FDA designated a Catalent Indiana manufacturing facility as Official Action Indicated (OAI), following a previous FDA rejection of its spinal muscular atrophy drug application.The Motley Fool · Oct 13, 2025

Why Scholar Rock Stock Raced 6% Higher TodayBank of America analyst Tazeen Ahmad initiated coverage on Scholar Rock, setting a buy rating with a $53 price target, which drove the stock up 6%. The analyst is particularly interested in the company's investigational spinal muscular atrophy (SMA) drug apitegromab.The Motley Fool · Oct 9, 2025

Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On FridayMultiple stocks saw significant gains on Friday, with Crinetics Pharmaceuticals leading the pack after FDA approval, while other companies like BlackBerry, Perpetua Resources, and Scholar Rock also experienced notable stock price increases.Benzinga · Sep 26, 2025

Why Scholar Rock Holding Stock Topped the Market TodayBiotech stock Scholar Rock (SRRK) jumped nearly 3% on Wednesday after a positive analyst note from Piper Sandler's Allison Bratzel. Bratzel believes the company's lead drug candidate, apitegromab, is undervalued and could see significant upside if approved for treating spinal muscular atrophy (SMA).The Motley Fool · Apr 23, 2025

Here's Why Everybody's Talking About Scholar Rock Right NowScholar Rock, a clinical-stage drugmaker, has developed a treatment candidate called apitegromab that prevents muscle loss. Results from a late-stage clinical trial suggest apitegromab can become a blockbuster-companion treatment for patients with a rare muscle-wasting disorder, leading to a 364% surge in the company's stock price.The Motley Fool · Oct 9, 2024

Wall Street Breakfast: The Week AheadThis article discusses the upcoming events in the financial world, including the Federal Reserve meeting, corporate earnings, IPOs, and investor events.Seeking Alpha · Apr 28, 2024

to start trading

SR

SRRKScholar Rock Holding Corporation Common Stock

SRRK

Pay with—

Available Balance0.00

Your PositionYou don't own any SRRK yet.

Related Tickers

Earnings